Skip to content
CompletedNot applicable

Dance and Movement Therapy in Patients With Schizophrenia

NCT05500651 · DMTinSchizo · Amasya University

Closed to entry
Status
Not accepting participants
Not applicable
Phase
30
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

Introduction: Schizophrenia is a mental disorder that starts at a young age and progresses with positive (hallucination, delusion) and negative (decreased emotional participation, reluctance) symptoms. While drug therapy in schizophrenia targets positive symptoms; psychotherapies are needed in the treatment of negative symptoms. It is seen that especially art therapies such as occupational and music support recovery and rehabilitation. In addition, it is stated that dance and movement therapy is effective in ensuring social participation of patients. There are a limited number of studies demonstrating the effect of dance and movement therapy on schizophrenia patients. Aim: This project was planned to examine the effects of dance and movement therapy techniques to be applied to patients with schizophrenia on patients' negative symptoms and disability. Method: In this project, which was planned in a repetitive measure design with a pretest-posttest control group, dance and movement therapy techniques, consisting of 12 sessions in total, will be applied to schizophrenic patients in a Community Mental Health Center once a week. Negative symptoms and disability levels will be determined before, after and a month after the application. The findings obtained as a result of these three follow-ups will be evaluated. Project Outputs: Reduction of negative symptoms and disability will enable schizophrenic patients to become individuals who can express themselves better in their family and society and have an increased quality of life. It is thought that these gains will increase patients' compliance with treatment, prevent recurrent symptoms and reduce hospitalizations. The results will also constitute a scientific source for the studies to be carried out in the field.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • The Scale for the Assessment of Negative Symptoms (SANS)

    Measured over 6 months

  • Disability Evaluation Schedule (WHO-DAS-II)

    Measured over 6 months

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

Not stated
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * have been diagnosed with schizophrenia for at least two years * not have been hospitalized in the past 3 months Exclusion Criteria: * have a therapy/psychoeducation program that they attend regularly * have a known physical or neurological disease * having just started the Community Mental Health Center

Where

1 study site

FacilityCityRegionCountry
Amasya Üniversitesi Sabuncuoğlu Şerefeddin Eğitim Ve Araştirma HastanesiAmasyaTurkey (Türkiye)

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT05500651 on ClinicalTrials.gov →

Last updated in the registry 2023-05-23. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

Indication